• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Study Results of Novel Inovio Electroporation Device for Gene Delivery Published in Vaccine Journal

Posted on: Tuesday, 27 September 2005, 06:00 CDT

Inovio Biomedical Corporation (AMEX: INO), a late stage developer of oncology and other therapies using electroporation to deliver drugs and nucleic acids, announced today that a scientific article presenting study data of a new device for combined injection and electroporation of plasmid DNA in large animals and humans was published in Vaccine, September, 2005. This study determined that electroporation of DNA using a novel injection/electroporation device resulted in efficient transfection and immune response in larger animals using mild electrical conditions and moderate amounts of DNA.

"DNA vaccines have the potential to be developed faster, address a broader range of diseases, and stimulate a more natural immunity than traditional vaccines. With strong pre-clinical evidence in large animals that electroporation can, compared to "naked" DNA, use lower doses and trigger faster immune responses that are stronger and more durable, we believe that electroporation has the potential to dramatically expand the market opportunity for DNA vaccines," said Avtar Dhillon, MD, Inovio's president and CEO. "We will continue to show leadership in optimizing devices, methods, and conditions intended to enable electroporation to be an efficient and safe non-viral delivery mechanism for therapeutic genes."

About Inovio Biomedical Corporation

Inovio Biomedical Corporation is a late stage biomedical company focused on building an oncology franchise based on its proprietary electrochemical tumor ablation system. The therapy targets a significant unmet clinical need: the selective killing of cancer cells and local ablation of solid tumors while preserving healthy tissue. Inovio is moving its lead product, the MedPulser(R), through pre-marketing studies for head and neck cancer and skin cancers in Europe, where it has CE Mark accreditation, a U.S. Phase III pivotal study for recurrent head and neck cancer, and a Phase I pancreatic cancer trial. Vical, University of Southampton, and H. Lee Moffitt Cancer Center are using Inovio's gene delivery technology in the first-ever clinical studies of novel DNA vaccines delivered using electroporation, which enhances local delivery and cellular uptake of useful biopharmaceuticals, and Merck is a development partner for the gene delivery technology. Inovio is a leader in electroporation, with 57 U.S. and 125 corresponding foreign issued patents, plus numerous pending patents in the U.S. and abroad. More information can be obtained at www.inovio.com.

This press release contains certain forward-looking statements relating to Inovio's plans to develop its electroporation drug and gene delivery technology and to maximize shareholder value. Actual events or results may differ from Inovio's expectations as a result of a number of factors, including the uncertainties inherent in clinical trials and product development programs, evaluation of potential opportunities, the level of corporate expenditures, the assessment of Inovio's technology by potential corporate partners, capital market conditions, and other factors set forth in Inovio's Annual Report on Form 10-K for the year ended December 31, 2004, and its Quarterly Report on Form 10-Q for the three months ended June 30, 2005, and other filings with the Securities and Exchange Commission. There can be no assurance that any product in the Inovio product pipeline will be successfully developed or manufactured, or that final results of clinical studies will be supportive of regulatory approvals required to market licensed products.

Source: Business Wire

More News in this Category